Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lysoderm is a topical cream formulation of lysozyme (specifically lysozyme hydrochloride), a naturally occurring enzyme with antibacterial, antiviral, and antifungal properties. Developed by Bosnalijek, Lysoderm is indicated for the local treatment of minor wounds, skin injuries, burns, and damaged skin to promote epithelialization and accelerate the healing process. It is also used to treat skin lesions of herpetic origin, diaper dermatitis, solar dermatitis (sunburn), and chronic wounds such as decubitus ulcers and diabetic skin ulcers. Lysozyme exerts its antimicrobial effect by hydrolyzing the beta-1,4-glycosidic bonds in the peptidoglycan of bacterial cell walls, leading to cell lysis, and by enhancing local non-specific immunity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lysozyme (Bosnalijek).